Dr. Berardo Francesca
Orthoptist / Assistant in Ophthalmology
Linea di ricerca:
Unità di ricerca:
Principali specializzazioni:
Medical activity: Works at IRCCS G.B. Bietti in the offices Via Livenza, 3 and Via di santo Stefano Rotondo 6, at Presidio Ospedaliero Britannico, Rome.
Scientific publication: PubMed
linkedin: Francesca Berardo
Graduated with honors in orthoptics and ophthalmological assistance (2008) at the Cattolica University, Rome.
In 2009 she attended a specialization course in “Visual Rehabilitation” at the University of Florence,
Faculty of Medicine and Surgery – Department of Oto-Neuro-Ophthalmological Surgery Sciences.
- 2016 to date – Permanent Contract as Orthoptist and assistant in ophthalmology at IRCCS G.B. Bietti
- 2013/2015 – Fixed term- Contract as Orthoptist and assistant in ophthalmology at IRCCS G.B. Bietti Research Unit Glaucoma
- 2010/2012 – Fellow as orthoptist and assistant in ophthalmology at IRCCS G.B. Bietti Research Unit Glaucoma
Technical support activities for scientific research of the Glaucoma Unit . Her main activity concerns the ophthalmic assistance in the field of instrumental diagnostics of glaucomatous pathology in clinical and research activity.
- Efficacy and safety assessment of T4030 eye drops versus Ganfort® UD in ocular hypertensive or glaucomatous patients. (THEA 2)
- Basic Human Research Study of Novel Glaucoma endpoints and identification of optimal patient populations for neuroprotection trials (CBASICR0031- NOVARTIS)
- A phase III, multinational, multicenter, investigator-masked, randomized, active-controlled trial, comparing the efficacy and safety of de-130a with xalatan® in patients with open-angle glaucoma or ocular hypertension over a 3-month period, followed by a 12-month follow-up with open-label de-130a treatment (CATIOPROST)
- A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03% / timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3)
- Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: Clinical effectiveness, tolerability and safety in a real world setting
- Efficacy and Safety Assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients. (THEA 1)
- • Efficacy of an ophthalmic solution based on taurine and hyaluronic acid in glaucomatous and ocular hypertensive patients in chronic therapy with ocular hypotonizing drugs.
- • Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV).
- • Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BMD) or Tafluprost Unit Dose Preservative Free 15microgram / ml (TUDPF) (Saflutan), in patients with Ocular hypertension or glaucoma suitable for prostaglandin therapy: A Randomized, single masked, 3 month cross-over, Investigator led, European multicentre Trial, II (SPORT II)
- • Clinical performance of Compass in the diagnosis of Glaucoma
- • A phase IV study on the changes in ocular signs and sympotms in patients with ocular hypertension or open angle glaucoma swiched from Ganfort eye drops to Taptiquom eye drops (SANTEN II)
- • Evaluation of BDNF and NGF levels in plasma and tears of patients with glaucoma, NTs and glaucoma.
- • Side effects of preservatives: clinical, cytological and instrumental evaluation of the ocular surface
- • Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in patients with Ocular hypertension or glaucoma: A Randomized, single masked, 3 month cross- over, Investigator led, European multicentre Trial (SPORT)
- •Comparison of the effect of bimatoprost-timolol fixed combination in reducing intraocular pressure versus fixed combinations of carbonic anhydrase inhibitors-timolol in patients with glaucoma or ocular hypertension not controlled by monotherapy: retrospective study
- • Efficacy of an ophthalmic solution based on cyanocobalamin, taurine and hyaluronic acid in patients receiving ocular hypotonizing drugs
- • To evaluate the effectiveness of Miotrab administered three times a day in reducing intraocular pressure
- • Lumigan 0.1 ® in daily outpatient activity: retrospective study
- • Learning effect of the Heidelberg Edge Perimeter (HEP) in patients with ocular hypertension
- • Influence of pupillary dilation in measurements of the retinal nerve fiber layer (RNFL), optic nerve head (ONH) and cell ganglion complex (GCC) with Optical Coherence Tomography (OCT) Spectral Domain (RTVue -100)
- • Prospective longitudinal study for the evaluation of the development of diseases on the ocular surface. Comparison between Treatment-Naive patients (not having received specific treatments) with ocular hypertension or glaucoma compared to patients without elevated ocular pressure. (SAHARA)
- • Evaluation of the therapeutic equivalence of Travoprost PR and Travatan, a double-blind randomized clinical trial in patients with glaucoma or ocular hypertension.
- • 2-year, multicenter, double-blind, randomized, parallel study on the safety of LUMIGAN® 0.1 mg / mL versus LUMIGAN® 0.3 mg / mL in patients with glaucoma or ocular hypertension.
- • A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolo 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given as individual monotherapies in patients with open angle glaucoma or ocular hypertension
- • Comparison between the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure to. Multi-Center Study Assessing Efficacy and Tollerability of TRAVATAN solution without BAK, containing Polyquad Preservative (0.004% travoprost) in Patients Previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution Monotherapy.
- • Evaluation of patients with altered retinal nerve fiber layer with SITA Standard perimetry and SITA SWAP perimetry.
- • A comparison between the Moorfields MDT and established perimeters to discriminate between normal and glaucomatous eyes
